Skip to content

Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin.

Trevor Steward

Trends in molecular medicine April 1, 2024 DOI: 10.1016/j.molmed.2023.12.001 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Psilocybin
Keywords Glp1 Eating disorders FMRI Orexin
Key findings Neuroimaging combined with peripheral endocrine measures can provide insights into the neurobiological drivers of eating disorders, and orexins/hypocretins, GLP1R agonists, and psilocybin are highlighted as avenues for investigation.

Abstract

The neurobiology of eating disorders [EDs; anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED)] remains poorly understood. Here, I describe how neuroimaging, accompanied by peripheral endocrine measures, can provide insights into the neurobiological drivers of eating disorders. Orexins/hypocretins, glucagon-like peptide-1 receptor (GLP1R) agonists, and psilocybin are highlighted as avenues for investigation.

Comparable studies

Other narrative reviews on psilocybin, most cited first.

Study Year Design Participants
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population 2019 Integrative review
The pharmacology of psilocybin 2002 Review
Serotonin research: contributions to understanding psychoses 2008 Review
Psychedelics, Meditation, and Self-Consciousness 2018 Review
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act 2018 Review

Citations in the library

Cited by 2

Cites 2

Related reading

Explore topics

Psilocybin